Journal of veterinary pharmacology and therapeutics最新文献_第9页

Gastrointestinal release site for delayed release and gelatin capsules in healthy dogs 健康狗胃肠道释放缓释胶囊和明胶胶囊的部位。

IF 1.5 4区农林科学

Journal of veterinary pharmacology and therapeutics Pub Date : 2024-03-22 DOI: 10.1111/jvp.13439

Charles B. Stone, Adam J. Rudinsky, Rebecca J. Urion, Simone B. March, Jenessa A. Winston

{"title":"Gastrointestinal release site for delayed release and gelatin capsules in healthy dogs","authors":"Charles B. Stone, Adam J. Rudinsky, Rebecca J. Urion, Simone B. March, Jenessa A. Winston","doi":"10.1111/jvp.13439","DOIUrl":"10.1111/jvp.13439","url":null,"abstract":"Gelatin capsules deliver their contents to the stomach, while delayed-release (DR) capsules are designed to allow delivery to the small intestine. This study evaluated the gastrointestinal release site of DR capsules in six healthy adult dogs compared to gelatin capsules. Both gelatin and DR capsules were filled with barium-impregnated polyethylene spheres (BIPS™), and following enteral administration, release site was assessed using abdominal radiographs at baseline, immediately after ingestion, 15 min post-ingestion, 30 min post-ingestion, and then every 30 min thereafter. The evaluated phases included fasted conditions (phase 1, n = 6), increased meal size (phase 2, n = 2), double encapsulation (phase 3, n = 2), and altered capsule size (phase 4, n = 1). The released site was the stomach in all phases for both capsule types. In phase 1, DR capsules had a significantly prolonged time (median 60 min, range 60–90) to release BIPS™ compared to gelatin capsules (15 min, range 15–30; p = .03). In phase 2 (full meal size), 3 (double encapsulation), and 4 (smaller capsule size) pilot studies, release time was prolonged but still occurred in the stomach. This is similar to the release site for gelatin capsules but differs from the release site for DR capsules in people. This has implications for pharmacologic outcomes for products that are affected by gastric physiology (e.g. fecal microbiota transplantation). Based on this pilot data, clinicians and researchers should not assume DR capsules will allow for intestinal delivery of contents in dogs. Future studies should be conducted on larger and varied populations of dogs.","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":"47 4","pages":"266-273"},"PeriodicalIF":1.5,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvp.13439","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140194084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetic characteristics of florfenicol in green sea turtles (Chelonia mydas) and hawksbill sea turtles (Eretmochelys imbricata) after intramuscular administration 绿海龟（Chelonia mydas）和玳瑁（Eretmochelys imbricata）肌肉注射氟苯尼考的药代动力学特征。

IF 1.5 4区农林科学

Journal of veterinary pharmacology and therapeutics Pub Date : 2024-03-22 DOI: 10.1111/jvp.13441

Pandaree Sitthiangkool, Amnart Poapolathep, Thanaphan Chomcheun, Oranee Jongkolpath, Kraisiri Khidkhan, Narumol Klangkaew, Napasorn Phaochoosak, Mario Giorgi, Saranya Poapolathep

{"title":"Pharmacokinetic characteristics of florfenicol in green sea turtles (Chelonia mydas) and hawksbill sea turtles (Eretmochelys imbricata) after intramuscular administration","authors":"Pandaree Sitthiangkool, Amnart Poapolathep, Thanaphan Chomcheun, Oranee Jongkolpath, Kraisiri Khidkhan, Narumol Klangkaew, Napasorn Phaochoosak, Mario Giorgi, Saranya Poapolathep","doi":"10.1111/jvp.13441","DOIUrl":"10.1111/jvp.13441","url":null,"abstract":"The pharmacokinetics of florfenicol (FFC) in green sea and hawksbill sea turtles were evaluated following intramuscular (i.m.) administration at two different dosages of 20 or 30 mg/kg body weight (b.w.). This study (longitudinal design) used 5 green sea and 5 hawksbill sea turtles for the two dosages. Blood samples were collected at assigned times up to 168 h. FFC plasma samples were analyzed using validated high-performance liquid chromatography equipped with diode array detection. The pharmacokinetic analysis was performed using a non-compartment approach. The FFC plasma concentrations increased with the dosage. The elimination half-life was similar between the treatment groups (range 19–25 h), as well as the plasma protein binding (range 18.59%–20.65%). According to the surrogate PK/PD parameter (T > MIC, 2 μg/mL), the 20 and 30 mg/kg dosing rates should be effective doses for susceptible bacterial infections in green sea and hawksbill sea turtles.","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":"47 4","pages":"300-307"},"PeriodicalIF":1.5,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140194085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reply to: Letter to the Editor from Malik et al.: Acute kidney injury following subcutaneous meloxicam administration 回复Malik等人致编辑的信：皮下注射美洛昔康后的急性肾损伤。

IF 1.3 4区农林科学

Journal of veterinary pharmacology and therapeutics Pub Date : 2024-03-10 DOI: 10.1111/jvp.13438

Alex Krekis, Jonathan N. King, Duncan D'Arcy-Howard, Nadene Stapleton, Jonathan Elliott, Ludovic Pelligand

引用次数: 0

Letter to the Editor: Acute kidney injury following subcutaneous meloxicam administration 致编辑的信：皮下注射美洛昔康后的急性肾损伤。

IF 1.3 4区农林科学

Journal of veterinary pharmacology and therapeutics Pub Date : 2024-03-01 DOI: 10.1111/jvp.13437

Richard Malik, Matthew K. Wun, Terence King, Rachel Korman

引用次数: 0

Pharmacokinetic report: Pharmacokinetics of a single oral dose of gabapentin in goats (Capra hircus) 药代动力学报告：山羊（Capra hircus）单次口服加巴喷丁的药代动力学。

IF 1.5 4区农林科学

Journal of veterinary pharmacology and therapeutics Pub Date : 2024-03-01 DOI: 10.1111/jvp.13436

Michael D. Kleinhenz, Darian Davis, Mikaela M. Weeder, Alyssa Leslie, Emily J. Reppert, Kushan Kompalage, Ryan Tucker, Johann F. Coetzee

{"title":"Pharmacokinetic report: Pharmacokinetics of a single oral dose of gabapentin in goats (Capra hircus)","authors":"Michael D. Kleinhenz, Darian Davis, Mikaela M. Weeder, Alyssa Leslie, Emily J. Reppert, Kushan Kompalage, Ryan Tucker, Johann F. Coetzee","doi":"10.1111/jvp.13436","DOIUrl":"10.1111/jvp.13436","url":null,"abstract":"Gabapentin is used in goats to treat chronic pain associated with lameness. However, pharmacokinetic data and clinical effectiveness trials are lacking. The objective of the study was to describe the pharmacokinetics of gabapentin in goats following a single oral dose. Six Spanish-crossbred goats were enrolled. Each goat was administered gabapentin at a target dose of 15 mg/kg per os. Serial blood samples were collected out to 60 h post-gabapentin administration for plasma gabapentin concentration determination. Plasma samples were analyzed for gabapentin concentration using ultra-high-pressure liquid chromatography coupled with mass spectroscopy. Individual animal pharmacokinetic outcomes were determined using non-compartmental analysis. Gabapentin was detectable in the plasma of all goats at 60 h post-administration. The mean (±SD) Cmax was 2.01 ± 0.62 μg/mL which occurred at 8.47 ± 1.9 h. The mean terminal half-life (T1/2) and mean resident time were determined to be 8.52 ± 1.8 and 18.7 ± 4.0 h, respectively. This study indicates gabapentin is absorbed from the gastrointestinal tract of goats. Further research is needed to determine an optimal dose for clinical efficacy in goats.","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":"47 4","pages":"294-299"},"PeriodicalIF":1.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvp.13436","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140012794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Florfenicol urinary excretion and its potential for treating canine urinary tract infections 氟苯尼考的尿排泄及其治疗犬尿路感染的潜力。

IF 1.3 4区农林科学

Journal of veterinary pharmacology and therapeutics Pub Date : 2024-02-29 DOI: 10.1111/jvp.13434

Kate S. KuKanich, Elayna E. Anderson, Astrid D. Carcamo Tzic, Butch KuKanich

{"title":"Florfenicol urinary excretion and its potential for treating canine urinary tract infections","authors":"Kate S. KuKanich, Elayna E. Anderson, Astrid D. Carcamo Tzic, Butch KuKanich","doi":"10.1111/jvp.13434","DOIUrl":"10.1111/jvp.13434","url":null,"abstract":"The canine urinary excretion of florfenicol was evaluated to explore its potential for treating urinary tract infections. Nine healthy male intact purpose-bred Beagles and four healthy client-owned dogs each received a single oral dose of florfenicol 20 mg/kg (300 mg/mL parenteral solution) with food. All voluntary urinations were collected for 12 h. Although florfenicol is reportedly bitter tasting, 7/9 Beagles and 4/4 client-owned dogs completely ingested the florfenicol and were enrolled; salivation (n = 1) and headshaking (n = 3) were observed. The last measured urine florfenicol concentrations were variable: Beagles (0.23–3.19 mcg/mL), Pug (3.01 mcg/mL) English Setter (21.29 mcg/mL), Greyhound (32.68 mcg/mL), and Standard Poodle (13.00 mcg/mL). Urine half-life was similar for the Beagles and the Pug, 0.75–1.39 h, whereas the half-life was 1.70–1.82 h for the English Setter, Greyhound, and Standard Poodle. Larger breed dogs exceeded 8 mcg/mL florfenicol (wild-type cutoff) in their urine at 12 h, whereas the Beagles and Pug had <8 mcg/mL; it is unclear if this is an individual, breed, or size difference. These data suggest oral florfenicol may need to be administered q6-12h for canine urinary tract infections, but further data are needed (more enrolled dogs, multiple-dose regimens) before considering clinical trials or breed-specific differences.","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":"47 3","pages":"168-174"},"PeriodicalIF":1.3,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139990484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetic evaluation of oral deracoxib in geese (Anser anser domesticus) 鹅（Anser anser domesticus）口服德拉克西布的药代动力学评估。

IF 1.3 4区农林科学

Journal of veterinary pharmacology and therapeutics Pub Date : 2024-02-29 DOI: 10.1111/jvp.13435

Charbel Fadel, Beata Łebkowska-Wieruszewska, Amnart Poapolathep, Firas Serih, Krzysztof Bourdo, Mario Giorgi

{"title":"Pharmacokinetic evaluation of oral deracoxib in geese (Anser anser domesticus)","authors":"Charbel Fadel, Beata Łebkowska-Wieruszewska, Amnart Poapolathep, Firas Serih, Krzysztof Bourdo, Mario Giorgi","doi":"10.1111/jvp.13435","DOIUrl":"10.1111/jvp.13435","url":null,"abstract":"The integration of pain management in veterinary practice, driven by heightened animal welfare concerns, extends to avian species where subtle and nonspecific behavioral signs pose challenges. Given that safety concerns with classical NSAIDs highlight the need for more targeted alternatives in birds, this study explores the pharmacokinetic (PK) properties of Deracoxib (DX), a COX-2 selective NSAID approved for use in dogs, following a single oral administration in geese. Six healthy female geese received 4 mg/kg DX. Blood was drawn from the left wing vein to heparinized tubes at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 24 h. Plasma DX concentrations were measured using HPLC coupled to an UV detector, and the data were pharmacokinetically analyzed using PKanalix™ software in a non-compartmental approach. The results indicated a terminal half-life of 6.3 h and a Tmax of 1 h, with no observed adverse effects. While refraining from claiming absolute safety based on a single dose, it is worth highlighting that further safety studies for DX in geese are warranted, suggesting a possibility for intermittent use. In addition, drawing conclusions on efficacy and suitability awaits further research, particularly in understanding COX-2 selectivity and protein binding characteristics specific to geese.","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":"47 3","pages":"231-234"},"PeriodicalIF":1.3,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139990485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of solubility profiles for pioneer and generic monensin premixes in biorelevant simulated intestinal fluid based on shake flask extractions 基于摇瓶提取法，比较先锋和通用莫能菌素预混剂在生物相关模拟肠液中的溶解度曲线。

IF 1.5 4区农林科学

Journal of veterinary pharmacology and therapeutics Pub Date : 2024-02-26 DOI: 10.1111/jvp.13432

Beverly J. Krabel, Laura B. Foust, Gary B. Fuller, Robert P. Hunter

{"title":"Comparison of solubility profiles for pioneer and generic monensin premixes in biorelevant simulated intestinal fluid based on shake flask extractions","authors":"Beverly J. Krabel, Laura B. Foust, Gary B. Fuller, Robert P. Hunter","doi":"10.1111/jvp.13432","DOIUrl":"10.1111/jvp.13432","url":null,"abstract":"In the United States, a generic Type A medicated article product can gain the FDA approval by demonstrating bioequivalence (BE) to the pioneer product by successfully conducting a blood level, pharmacodynamic, or clinical BE study. A biowaiver can be granted based on several criteria, assuming the dissolution of the test and reference products represents the only factor influencing the relative bioavailability of both products. Monensin is practically insoluble in H2O per the USP definition. Previously published data from a comparison study of monensin dissolution profiles from the pioneer product and four generic products using biorelevant media showed that generic monensin products demonstrated different dissolution profiles to the pioneer product in these USP biorelevant rumen media. This follow-up study compared the solubility profiles in simulated intestinal fluid (cFaSSIF, pH 7.5) for the pioneer product and four generic products. The generic monensin products demonstrated different in vitro dissolution profiles to the pioneer product in biorelevant media. The differences demonstrated in solubility and dissolution profiles are of concern regarding the potential efficacy of generic monensin in cattle. There are also additional concerns for the potential development of Eimeria resistance in cattle receiving a sub-therapeutic dose of monensin from a less soluble generic product.","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":"47 4","pages":"288-293"},"PeriodicalIF":1.5,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139972458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bayesian estimation in veterinary pharmacology: A conceptual and practical introduction 兽医药理学中的贝叶斯估计：概念和实践介绍。

IF 1.5 4区农林科学

Journal of veterinary pharmacology and therapeutics Pub Date : 2024-02-22 DOI: 10.1111/jvp.13433

Andrew P. Woodward

{"title":"Bayesian estimation in veterinary pharmacology: A conceptual and practical introduction","authors":"Andrew P. Woodward","doi":"10.1111/jvp.13433","DOIUrl":"10.1111/jvp.13433","url":null,"abstract":"Sophisticated mathematical and computational tools have become widespread and important in veterinary pharmacology. Although the theoretical basis and practical applications of these have been widely explored in the literature, statistical inference in the context of these models has received less attention. Optimization methods, often with frequentist statistical inference, have been predominant. In contrast, Bayesian statistics have not been widely applied, but offer both practical utility and arguably greater interpretability. Veterinary pharmacology applications are generally well supported by relevant prior information, from either existing substantive knowledge, or an understanding of study and model design. This facilitates practical implementation of Bayesian analyses that can take advantage of this knowledge. This essay will explore the specification of Bayesian models relevant to veterinary pharmacology, including demonstration of prior selection, and illustrate the capability of these models to generate practically useful statistics, including uncertainty statements, that are difficult or impossible to obtain otherwise. Case studies using simulated data will describe applications in clinical trials, pharmacodynamics, and pharmacokinetics, all including multilevel modeling. This content may serve as a suitable starting point for researchers in veterinary pharmacology and related disciplines considering Bayesian estimation for their applied work.","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":"47 4","pages":"322-352"},"PeriodicalIF":1.5,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvp.13433","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139931730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Application of eprinomectin-containing parasiticides at label doses causes neurological toxicosis in cats homozygous for ABCB11930_1931del TC 在ABCB11930_1931del TC基因同源的猫体内施用标签剂量的含依普霉素的杀寄生虫药会导致神经系统中毒。

IF 1.3 4区农林科学

Journal of veterinary pharmacology and therapeutics Pub Date : 2024-02-17 DOI: 10.1111/jvp.13431

Katrina L. Mealey, Neal S. Burke, Nicolas F. Villarino, Michael H. Court, Jennifer P. Heusser

{"title":"Application of eprinomectin-containing parasiticides at label doses causes neurological toxicosis in cats homozygous for ABCB11930_1931del TC","authors":"Katrina L. Mealey, Neal S. Burke, Nicolas F. Villarino, Michael H. Court, Jennifer P. Heusser","doi":"10.1111/jvp.13431","DOIUrl":"10.1111/jvp.13431","url":null,"abstract":"The feline MDR1 mutation (ABCB11930_1931delTC) has been associated with neurological toxicosis after topical application of eprinomectin products labeled for feline use. Information was collected from veterinarians who submitted samples for ABCB11930_1931delTC genotyping. In most cases, the submission form indicated an adverse event involving eprinomectin, in other cases submitting veterinarians were contacted to determine whether the patient had experienced an adverse drug event involving eprinomectin. If so, additional information was obtained to determine whether the case met inclusion criteria. 14 cases were highly consistent with eprinomectin toxicosis. Eight cats were homozygous for ABCB11930_1931del TC (3 died; 5 recovered). Six cats were homozygous wildtype (2 died; 4 recovered). The observed ABCB11930_1931delTC frequency (57%) was higher than the expected frequency (≤1%) in the feline population (Fisher Exact test, p < 0.01). Among wildtype cats, four were concurrently treated with potential competitive inhibitors of P-glycoprotein. Results indicate that topical eprinomectin products, should be avoided in cats homozygous for ABCB11930_1931delTC. This is a serious, preventable adverse event occurring in an identifiable subpopulation treated with FDA-approved products in accordance with label directions. Acquired P-glycoprotein deficiency resulting from drug interactions may enhance susceptibility to eprinomectin-induced neurological toxicosis in any cat, regardless of ABCB1 genotype.","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":"47 3","pages":"226-230"},"PeriodicalIF":1.3,"publicationDate":"2024-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvp.13431","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139746837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0